TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Dermata Therapeutics ( (DRMA) ) is now available.
On November 17, 2025, Dermata Therapeutics announced the termination of its License Agreement with Villani, Inc., effective 90 days after Villani’s receipt of the notice. This decision aligns with Dermata’s strategic shift towards over-the-counter skincare treatments and withdrawal of its investigational drug application with the FDA, impacting its operational focus and stakeholder expectations.
The most recent analyst rating on (DRMA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.
Spark’s Take on DRMA Stock
According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.
Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.
To see Spark’s full report on DRMA stock, click here.
More about Dermata Therapeutics
Dermata Therapeutics operates in the biotechnology industry, focusing on developing and commercializing skincare treatments. The company’s primary products include over-the-counter skincare treatments, and it has recently shifted its market focus away from investigational new drug applications.
Average Trading Volume: 137,787
Technical Sentiment Signal: Sell
Current Market Cap: $2.09M
For an in-depth examination of DRMA stock, go to TipRanks’ Overview page.